Hyperpolarized Xenon-129

Phase 3Small molecule

TThunder Bay Regional Health Research Institute

Hyperpolarized Xenon-129 is one of 51 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

BiomarkerRecruiting

Cystic FibrosisPhase 3

Active, not recruiting

BiomarkerPhase 3

Recruiting

Competition

Competitive Landscape

105 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Biaxin

AbbVie

Phase 2

2 3

Lamprene

Novartis

Phase 2

1 4

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 5

Tygacil

PPrism Pharmaceuticals

Phase 2

1 6

Sirturo

WWim Janssens

Phase 2

1 7

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

19 8

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 9

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 10

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalActive, not recruiting

Cystic Fibrosis

NCT04467957

Q4 2032

Phase 2/3Recruiting

Biomarker

NCT06856525

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

Terminated·TThunder Bay Regional Health Research Institute·Phase 1·NCT02638519·51 enrolled

Biomarker1 trial

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Recruiting·—·Phase 2/3·NCT06856525·80 enrolled

Cystic Fibrosis1 trial

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Active, not recruiting·—·Phase 4·NCT04467957·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Hyperpolarized Xenon-129. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized Xenon-129 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized Xenon-129. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thunder Bay Regional Health Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThunder Bay Regional Health Research Institute

Hyperpolarized Xenon-129

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2032

Trials by Indication[1]

Alzheimer's Disease1 trial

Biomarker1 trial

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News